Document is current
Any future updates will be listed below
-
Authors
Succaria, Farah
Kvistborg, Pia
Stein, Julie E.
Engle, Elizabeth L.
McMiller, Tracee L.
Rooper, Lisa M.
Thompson, Elizabeth
Berger, Alan E.
van den Brekel, Michiel
Zuur, Charlotte L.
Haanen, John
Topalian, Suzanne L.
Taube, Janis M. https://orcid.org/0000-0002-8273-4395
-
Funding
Funding for this research was provided by:
National Cancer Institute (R01 CA142779)
Bristol-Myers Squibb Foundation (IION network)
Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
- License Information
-
More Information
Article History
Received: 18 February 2020
Accepted: 12 October 2020
First Online: 30 October 2020
Compliance with ethical standards
:
: J. M. Taube reports consulting/advisory board for BMS, Merck, AstraZeneca, and Compugen; research funding through Bristol Myers Squibb; and reagents and machine loan from Akoya Biosciences. S. L. Topalian reports stock and other ownership interests in Aduro Biotech, DNAtrix, Dracen Pharmaceuticals, Dragonfly Therapeutics, Ervaxx, Five Prime Therapeutics, Potenza Therapeutics, RAPT, Tizona Therapeutics, Trieza Therapeutics, and WindMIL; a consulting or advisory role in Amgen, DNAtrix, Dragonfly Therapeutics, Dynavax, Ervaxx, Five Prime Therapeutics, Immunocore, Immunomic Therapeutics, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Merck, RAPT, and WindMIL; research grants from Bristol Myers Squibb and Compugen; patents, royalties, and/or other intellectual property through her institution with Aduro Biotech, Arbor Pharmaceuticals, Bristol Myers Squibb, Immunomic Therapeutics, NexImmune, and WindMIL; and travel, accommodations, and expenses from Bristol-Myers Squibb and Five Prime Therapeutics. P. Kvistborg is a consultant for Neon Therapeutics and Personalis and a recipient of grant/research support from Bristol-Myers Squibb and Merck. J. Haanen: NKI received financial compensation for advisory role of J. Haanen with AZ, Amgen, Bayer, BMS, Celsius Therapeutics, MSD, Merck Serono, Pfizer, Roche/Genentech, Neon Therapeutics, lmmunocore, Seattle Genetics, Novartis, GSK. Also, NKI received research grants through J. Haanen from BMS, MSD, Novartis, and Neon Therapeutics. J. Stein reports consulting (uncompensated) for AstraZeneca. No potential conflicts of interest were disclosed by the other authors.
: The local Ethics Committees of the Netherlands Cancer Institute (NKI) and Johns Hopkins University (JHU) approved this study. The study is retrospective in nature and all procedures performed were part of routine care.
